Cyclopeptide Utilizing Patents (Class 514/2.9)
-
Publication number: 20140315790Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.Type: ApplicationFiled: April 17, 2013Publication date: October 23, 2014Inventors: Simon Bushell, Matthew J, LaMarche, Michael A. Patane, Lewis Whitehead
-
Publication number: 20140308347Abstract: The present invention relates to compounds that are cationic vancomycin analogues and their compositions. Method of making the compounds and their use as medicament for the treatment of bacterial infection are also disclosed.Type: ApplicationFiled: November 13, 2012Publication date: October 16, 2014Applicant: JAWAHARLAL NEHRU CENTRE FOR ADVANCEDInventors: Jayanta Haldar, Yarlagadda Venkateswarlu, Padma Akkapeddi
-
Publication number: 20140303071Abstract: The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.Type: ApplicationFiled: June 20, 2014Publication date: October 9, 2014Inventor: Deborah O'NEIL
-
Publication number: 20140294925Abstract: Provided herein are methods of treating a superbug infection in a subject that include administering to the subject a therapeutically effective dose of ramoplanin in combination with a therapeutically effective dose of one or more rhamnolipids, thereby treating the superbug infection. The superbug may be vancomycin-resistant Enterococcus, Clostridium difficile, or multidrug-resistant Clostridium difficile. The one or more rhamnolipids may include monorhamnolipid Rha-C10-C10, dirhamnolipid Rha-Rha-C10-C10, or monorhamnolipid Rha-C10-C10 and dirhamnolipid Rha-Rha-C10-C10. Also disclosed are pharmaceutical compositions that include ramoplanin, one or more rhamnolipids, and a pharmaceutically acceptable carrier, as well as formulations for preventing superbug infection.Type: ApplicationFiled: March 7, 2014Publication date: October 2, 2014Applicant: AGAE Technologies LLCInventor: Xihou Yin
-
Publication number: 20140296133Abstract: The invention discloses silaanalogs of oxazolidinone compounds, to pharmaceutical compositions and to the synthesis of the oxazolidinone derivatives of formula I. The invention further relates to methods of treating a subject suffering with gram positive pathogens including those resistant to methicillin and vancomycin using the compound(s) or modulation of coagulation properties of blood-clotting cascade or compositions of the oxazolidinone derivatives of the invention.Type: ApplicationFiled: October 11, 2012Publication date: October 2, 2014Applicant: Council of Scientific & Industrial ResearchInventors: Dumbala Srinivasa Reddy, Seetharam Singh Balamkundu, Remya Ramesh
-
Publication number: 20140296134Abstract: Embodiments include methods for generating a metabolite profile of a stool sample and methods of assessing the status of a subject using the metabolic profile derived from a stool sample.Type: ApplicationFiled: November 8, 2012Publication date: October 2, 2014Applicant: The Board of Regents of the University of Texas SystemInventors: Tor Savidge, Sara Dann
-
Patent number: 8846610Abstract: The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions.Type: GrantFiled: July 31, 2013Date of Patent: September 30, 2014Assignee: Cubist Pharmaceuticals, Inc.Inventors: Dennis Keith, Jan-Ji Lai, Chandrika Govardhan, Nazer Khalaf
-
Publication number: 20140274881Abstract: Compositions that include antimicrobial agents and biodegradable delivery vehicles adapted to enter a cell and release the antimicrobial agents in the cell as they biodegrades. Also provided are compositions that include first and second delivery vehicles including first and second antimicrobial agents, wherein the first delivery vehicles are adapted to release the first antimicrobial agents at a rate that differs from that at which the second delivery vehicles release the second antimicrobial agents, articles of manufacture that include one or more biodegradable delivery vehicles, and methods of making and using the compositions to treat intracellular and/or extracellular infections are disclosed.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Applicants: CAROLINAS HEALTHCARE SYSTEM, THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTEInventors: Kenneth E. Gonsalves, Michael J. Bosse, John Kent Ellington, Michael Hudson, James Horton
-
Patent number: 8835382Abstract: The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.Type: GrantFiled: November 23, 2010Date of Patent: September 16, 2014Assignee: Cubist Pharmaceuticals, Inc.Inventors: Sandra O'Connor, Sophie Sun, Gaauri Naik
-
Publication number: 20140256616Abstract: Modified green tea polyphenols and methods of their use are provided. One aspect provides compounds and compositions containing green tea polyphenols with one on more ester-linked fatty acids.Type: ApplicationFiled: May 19, 2014Publication date: September 11, 2014Applicant: Georgia Regents Research Institute, Inc.Inventor: Stephen D. Hsu
-
Publication number: 20140256617Abstract: A hydrogel (I), comprising a polymer backbone wherein an aqueous solution of the hydrogel comprises a first lower critical solution temperature, and wherein the hydrogel is configured to be converted in vivo into a modified hydrogel, and wherein an aqueous solution of the modified hydrogel comprises a second lower critical solution temperature, and wherein the second lower critical solution temperature is greater than the first lower critical solution temperature.Type: ApplicationFiled: October 12, 2012Publication date: September 11, 2014Inventors: Derek Overstreet, Brent Vernon, Ryan McLemore, Alex McLaren
-
Patent number: 8828413Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula I: The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.Type: GrantFiled: February 24, 2010Date of Patent: September 9, 2014Assignee: New York UniversityInventors: Kent Kirshenbaum, Sung Bin Shin
-
Publication number: 20140206602Abstract: The invention provides bipartite inhibitors of bacterial RNA polymerase having the general structural formula (I): X-?-Y (I) wherein X is an moiety that binds to the rifamycin binding site of a bacterial RNA polymerase, Y is a moiety that binds to the GE23077 binding site of a bacterial RNA polymerase, and is a linker. The invention also provides compositions comprising such compounds, methods of making such compounds, and methods of using said compounds. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.Type: ApplicationFiled: June 20, 2012Publication date: July 24, 2014Inventors: Richard H. Ebright, David Degen, Yu Zhang, Yon Ebright
-
Patent number: 8785375Abstract: The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.Type: GrantFiled: August 22, 2012Date of Patent: July 22, 2014Assignee: Novabiotics Ltd.Inventor: Deborah O'Neil
-
Patent number: 8778873Abstract: The invention describes a pharmaceutical composition to combat multiple-drug-resistant bacteria in non-ocular infective conditions. Compositions comprising glycopeptides, in particular vancomycin, and cephalosporins, in particular ceftriaxone, are disclosed. Such compositions are found to be useful for parenteral administration for hospitalized patients with serious infections. Specifically, this invention also discloses a pharmaceutical composition further including an excipient such as CVMC agent and is available in dry powder form for reconstitution before injection with a suitable solvent. The pharmaceutical compositions of this invention have been found normally to enhance resistance to precipitation in solutions to be administered parenterally. The invention also gives details of the dosage forms stored in sealed containers to be reconstituted before use.Type: GrantFiled: April 27, 2011Date of Patent: July 15, 2014Assignee: Venus Remedies LimitedInventor: Manu Chaudhary
-
Publication number: 20140194345Abstract: The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.Type: ApplicationFiled: December 3, 2013Publication date: July 10, 2014Inventors: Aaron J. Peoples, Dallas Hughes, Losee Lucy Ling, William Millett, Anthony Nitti, Amy Spoering, Victoria Alexandra Steadman, Jean-Yves Christophe Chiva, Linos Lazarides, Michael Kenyon Jones, Karine Gaelle Poullenec, Kim Lewis
-
Patent number: 8772445Abstract: A compound having the general structure R1, R2, R3 and R4 being selected from the group consisting of a hydrogen atom (H) and a C1-C20 alkyl, and R5 being a phenyl radical.Type: GrantFiled: November 20, 2008Date of Patent: July 8, 2014Assignee: Helmholtz-Zentrum Fuer Ozeanforschung Kiel (Geomar)Inventors: Johannes Imhoff, Zhiguo Yu, Gerhard Lang, Jutta Wiese, Holger Kalthoff, Stefanie Klose
-
Publication number: 20140187475Abstract: A composition suitable for application to the skin comprising at least one lantibiotic, an acidic external phase aqueous solution, at least one pharmaceutically acceptable internal phase carrier material, and a combination thereof. A method for preventing or treating mastitis, comprising administering to a human in need of such treatment a topical composition comprising a therapeutically-effective amount of at least one lantibiotic, an acidic aqueous solution, and at least one pharmaceutically acceptable carrier material.Type: ApplicationFiled: December 31, 2013Publication date: July 3, 2014Inventors: Thomas W. Hale, Brian Warren, Brian Silver
-
Patent number: 8765907Abstract: The invention relates to a compound of the general structure (I), where R is a hydrogen atom (II) or an unsubstituted, monosubstituted or polysubstituted C1-C20-alkyl, wherein the alkyl is straight, branched, cyclic and/or partially unsaturated, or an unsubstituted, monosubstituted or polysubstituted phenyl group.Type: GrantFiled: April 30, 2010Date of Patent: July 1, 2014Assignee: Geomar Helmholtz-Zentrum fur Ozeanforschung KielInventors: Johannes Imhoff, Inga Knopf-Kajahn, Gerhard Lang, Jutta Wiese, Arne Peters
-
Publication number: 20140171358Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used alone or in combination with one or more antibiotic agents for the treatment of disease and/or disorders such as a skin infection or wound healing.Type: ApplicationFiled: February 21, 2014Publication date: June 19, 2014Applicant: Dignity Sciences LimitedInventors: Mehar Manku, John Climax, Jonathan Rowe, David Coughlan
-
Publication number: 20140171357Abstract: The invention features vancomycin class compounds modified to be suitable for oral delivery or to possess increased antimicrobial potency, formulations for the oral administration of vancomycin class compounds, and synthetic methods for making vancomycin class compounds.Type: ApplicationFiled: March 23, 2012Publication date: June 19, 2014Applicant: Seachaid Pharmaceuticals, Inc.Inventors: Balasingam Radhakrishnan, Ronald George Sherrill, Kenneth Duke James, JR.
-
Publication number: 20140162939Abstract: The invention provides compounds of formula (I): and salts thereof, wherein X and Y have any of the values defined herein. The compounds inhibit bacterial RNA polymerase, inhibit bacterial growth, and have applications in, analysis of RNA polymerase structure and function, control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, antibacterial therapy, and drug discovery.Type: ApplicationFiled: December 12, 2013Publication date: June 12, 2014Inventors: Richard H. Ebright, Yon W. Ebright, Yu Feng, David Degen
-
Publication number: 20140162940Abstract: The invention provides bipartite inhibitors of bacterial RNA polymerase that contain: (i) a first moiety that binds to the salinamide binding site of a bacterial RNA polymerase; (ii) a second moiety comprising a nucleoside analog; and (iii) a linker connecting said first and second moieties.Type: ApplicationFiled: December 12, 2013Publication date: June 12, 2014Inventors: Richard H. Ebright, Yu Feng, Yu Zhang
-
Publication number: 20140142029Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: November 21, 2013Publication date: May 22, 2014Applicant: RQx Pharmaceuticals, Inc.Inventors: Tucker Curran ROBERTS, Peter Andrew SMITH, Robert I. HIGUCHI, David CAMPBELL, Prasuna PARASELLI
-
Publication number: 20140142031Abstract: The present invention relates to novel anti-TB cyclic peptides from Nonomuraea sp. MJM5123, a process for the production of the anti-Tuberculosis peptide and a pharmaceutical composition for the prevention and treatment of mycobacterial infection comprising the same. The composition of the present invention is highly active against replicating/non-replicating M. tuberculosis, including MDR and XDR strains, so that it can be effectively used as a therapeutic agent for tuberculosis.Type: ApplicationFiled: April 18, 2012Publication date: May 22, 2014Inventors: Jong Woo Kim, Sang Wook Lee, Sang jin Park, Joo Won Suh, In Ae Lee, Tae Mi Yoon, Jong Keun Choi, Ji Ean Lee, Jin Yong Kim, Ying Yu Jin, Scott Franzblau, Sanghyum Cho, Wei Gao, Guido Pauli, James McAlpine, Jose Napolitano, Birgit Jaki, Brent Friesen, Maria Florencia Rodriguez Brasco, David Lankin
-
Patent number: 8729031Abstract: Compounds of formula (IV) and pharmaceutical compositions comprising the same are described, wherein X1 and X2, R3, L, Ar1, p and Z have the values disclosed herein.Type: GrantFiled: February 2, 2010Date of Patent: May 20, 2014Assignee: Novacta Biosystems LimitedInventor: Sjoerd Nicolaas Wadman
-
Publication number: 20140113005Abstract: The present disclosure relates to pyrazine compounds of formula I: wherein L, n, R1, and R2 are as described in the specification. These compounds are useful as inhibitors of ATR protein kinase. The disclosure also relates to pharmaceutically acceptable compositions comprising the compounds of the disclosure; methods of treating of various diseases, disorders, and conditions using the compounds of the disclosure; processes for preparing the compounds of the disclosure; intermediates for the preparation of the compounds of the disclosure; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.Type: ApplicationFiled: January 16, 2013Publication date: April 24, 2014Applicant: Vertex Pharmaceuticals IncorporatedInventor: Vertex Pharmaceuticals Incorporated
-
Patent number: 8697638Abstract: The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions.Type: GrantFiled: August 26, 2008Date of Patent: April 15, 2014Assignee: Cubist Pharmaceuticals, Inc.Inventors: Dennis Keith, Jan-Ji Lai, Chandrika Govardhan, Nazer Khalaf
-
Patent number: 8697639Abstract: The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compounds (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of using the same in research, therapeutic and drug screening applications.Type: GrantFiled: April 13, 2009Date of Patent: April 15, 2014Assignee: Biosynexus IncorporatedInventors: Scott M. Walsh, Mary C. Pittaway, James J. Mond
-
Publication number: 20140100157Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.Type: ApplicationFiled: December 10, 2013Publication date: April 10, 2014Applicant: THE MEDICINES COMPANYInventors: Mark Harvey WILCOX, Simon BAINES, Dario LEHOUX, Thomas R. PARR
-
Publication number: 20140094402Abstract: The present invention concerns novel lantibiotic compounds, processes for the isolation and preparation thereof, pharmaceutical compositions containing the same, pharmaceutical acceptable salts thereof, and methods of use of the lantibiotics as antibacterial agents.Type: ApplicationFiled: March 30, 2012Publication date: April 3, 2014Applicant: SENTINELLA PHARMACEUTICALS, INC.Inventors: Sonia Ilaria Maffioli, Matteo Simone, Paolo Monciardini, Eleonora Gaspari
-
Publication number: 20140094403Abstract: Provided herein are inventive enopeptin compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Further provided are methods of preparation, use, and treatment.Type: ApplicationFiled: March 30, 2012Publication date: April 3, 2014Applicant: Brown UniversityInventor: Jason K. Sello
-
Patent number: 8685917Abstract: The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.Type: GrantFiled: July 8, 2010Date of Patent: April 1, 2014Assignee: Enanta Pharmaceuticals, Inc.Inventors: Xuri Gao, Yat Sun Or, Guoqiang Wang, Jiang Long
-
Patent number: 8680234Abstract: The present invention relates to a polymyxin derivative wherein R1, R2 and R3 are optional and R1, R2, R3, R5, R8 and R9 are cationic or neutral amino acid residues selected so that the total number of positive charges at physiological pH is at least two but no more than three; and to a combination product comprising at least two such derivatives.Type: GrantFiled: July 23, 2010Date of Patent: March 25, 2014Assignee: Northern Antibiotics OyInventors: Martti Sakari Vaara, Timo Ilmari Vaara
-
Publication number: 20140073559Abstract: Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds.Type: ApplicationFiled: March 15, 2013Publication date: March 13, 2014Applicants: Cubist Pharmaceuticals, Inc., BioSource Pharm, Inc.Inventors: BioSource Pharm, Inc., Cubist Pharmaceuticals, Inc.
-
Publication number: 20140073558Abstract: The present invention relates to novel lipopeptide compounds, pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The compounds of the invention are particularly useful against a variety of bacteria, including resistant strains. The compounds are useful as antibacterial agents against Clostridium difficile.Type: ApplicationFiled: June 12, 2013Publication date: March 13, 2014Applicant: CUBIST PHARMACEUTICALS, INC.Inventors: Chester A. Metcalf, III, Jing Li, Andre Lee Pearson
-
Publication number: 20140066364Abstract: A tissue adhesive including cyanoacrylate and polyethylene glycol (PEG), wherein the PEG remains a polyether and wherein the tissue adhesive is bioabsorbable. A tissue adhesive including cyanoacrylate bulk monomer and cyanoacrylate nanoparticles containing a therapeutic therein. A kit for applying tissue adhesive, including the tissue adhesive described above and an applicator. Methods of accelerating degradation of a cyanoacrylate tissue adhesive applying a tissue adhesive, closing an internal wound, administering a therapeutic to tissue, treating cancer, and preventing infection in a wound. Methods of method of making a bioabsorbable tissue adhesive and making a therapeutic tissue adhesive.Type: ApplicationFiled: November 8, 2013Publication date: March 6, 2014Applicant: Adhezion Biomedical, LLCInventors: Jeoung Soo Lee, Charles Kenneth Webb, Robert Zimmerman, Rafael Ruiz, SR.
-
Publication number: 20140066365Abstract: A product comprising at least one given antibiotic and a calixarene for use as medicament.Type: ApplicationFiled: April 11, 2012Publication date: March 6, 2014Inventors: Marion Grare, Raphaël, Emmanuel Duval
-
Publication number: 20140050777Abstract: The present invention provides novel liposomal formulations of polymyxin B and pharmaceutical compositions thereof useful for the treatment of bacterial infections. The liposomal formulation comprises a lipid component formed as vesicles each having a minimum size of at least 500 nm and polymyxin B encapsulated in the vesicles. The present invention also provides a drug delivery system that comprises a plurality of liposomes encapsulating a polymyxin B therein, where the liposomes have a minimum vesicular size of at least 500 nm. The liposomes comprising the drug delivery system are useful to increase efficacy of a treatment for a bacterial infection by increasing bioavailability and distribution of the polymyxin B within the subject.Type: ApplicationFiled: May 22, 2013Publication date: February 20, 2014Inventors: Vincent Tam, Diana Chow, Jie He
-
Patent number: 8648169Abstract: The present invention relates to methods of treating or preventing retinal ganglion cell (RGC) death and/or glaucoma using modulators of neurotrophic receptors that comprise ?-turn peptidomimetic cyclic compounds or derivatives thereof. The neurotrophic receptor modulators can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat or prevent ocular hypertension, RGC death and/or glaucoma.Type: GrantFiled: December 5, 2007Date of Patent: February 11, 2014Assignee: The Royal Institution for the Advancement of Learning/McGill UniversityInventor: H. Uri Saragovi
-
Patent number: 8642535Abstract: The present invention relates to a polymyxin derivative wherein the derivative has a total of three positive charges at physiological pH and wherein the terminal moiety (D) of the derivative comprises a total of 1 to 5 carbon atoms. The invention also relates to a method of treating a subject for a gram-negative bacterial infection by administering a polymyxin derivative of the invention in combination with a second antibacterial agent. Finally, the invention relates to a process for preparing such polymyxin derivatives.Type: GrantFiled: May 2, 2012Date of Patent: February 4, 2014Assignee: Northern Antibiotics Ltd.Inventors: Martti Sakari Vaara, Timo Ilmari Vaara
-
Publication number: 20140030242Abstract: Disclosed are a novel strain with antibacterial activity, identified as Streptomyces sp. AN1542 strain (Accession No.: KCTC 12113BP), an antibacterial composition comprising a compound represented by Chemical Formula 1 or 2, or a strain producing the same as an active ingredient, and a method for producing the same. Exhibiting potent antibacterial activity against pathogenic microbes and antibiotic-resistant microbes, particularly, MRSA, QRSA, VRSA and VRE, the compound or the strain of the present invention can be applied to the treatment of infectious diseases caused by superbacteria.Type: ApplicationFiled: January 4, 2012Publication date: January 30, 2014Inventors: Won Gon Kim, Yun Ju Kwon, Mi Jin Sohn
-
Patent number: 8637451Abstract: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis.Type: GrantFiled: December 29, 2011Date of Patent: January 28, 2014Assignee: Synergy Pharmaceuticals Inc.Inventors: Kunwar Shailubhai, Gregory Nikiforovich, Gary S. Jacob
-
Publication number: 20140024577Abstract: The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions.Type: ApplicationFiled: June 27, 2013Publication date: January 23, 2014Inventors: Dennis Keith, Ja-Ji Lai, Chandrika Govardhan, Nazer Khalaf
-
Patent number: 8629100Abstract: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.Type: GrantFiled: July 24, 2013Date of Patent: January 14, 2014Assignee: The Medicines CompanyInventors: Mark Harvey Wilcox, Simon Baines, Dario Lehoux, Thomas R. Parr
-
Publication number: 20130345121Abstract: Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin B1 and [Ile7] polymyxin B1. The novel compounds have antibacterial properties against a diverse range of gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin B. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds.Type: ApplicationFiled: December 21, 2012Publication date: December 26, 2013Applicant: BioSource Pharm, Inc.Inventor: BioSource Pharm, Inc.
-
Patent number: 8614193Abstract: The subject application pertains to a compound of structure IX or X: or a pharmaceutically acceptable salt thereof, wherein: X is —C(?O)N(R10)— or —CH(OPr3) —; R7, R9 and R10 are the same or different and represent hydrogen or an amino acid side chain moiety from either a natural or an unnatural amino acid; Pr1 and Pr2 are the same or different and represent hydrogen or a thiol protecting group; Pr3 is hydrogen or an alcohol protecting group; R1, R2, R5 and R6 are the same or different and represent hydrogen or an amino acid side chain moiety from either a natural or an unnatural amino acid, or R1 and R2 and/or R5 and R6, taken together with the carbon atom to which they are attached, form a spirocyclic moiety, with the proviso that: each of R1 and R2 is not hydrogen, or each of R5 and R6 is not hydrogen.Type: GrantFiled: May 22, 2009Date of Patent: December 24, 2013Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Franck Alexandre Silva, Cyrille Davy Tomassi, Alexander Richard Liam Cecil, Thomas James Hill
-
Patent number: 8614179Abstract: There is described a composition comprising a therapeutically active imidazole, and derivatives thereof, and an agent active on a bacterial cell surface selected from the group consisting of one or more of colistin, nisin, D-cycloserine, fosfomycin, fosfomycin trometamol, fosfomycin disodium and polymixin B, and derivatives thereof.Type: GrantFiled: July 17, 2009Date of Patent: December 24, 2013Assignee: E-Therapeutics PLCInventors: Malcolm Philip Young, Catherine Mary Thomas
-
Publication number: 20130338059Abstract: This disclosure relates to methods for differentiating between mammals having active and latent Tuberculosis disease, by determining the percentage of polyfunctional CD4+ T-cells expressing TNF-alpha, IFN-gamma, and IL-2, or by determining expression of IL-17.Type: ApplicationFiled: December 22, 2011Publication date: December 19, 2013Applicant: Centre Hospitalier Universitaire VaudoisInventors: Giuseppe Pantaleo, Alexandre Harari, Matthieu Perreau
-
Patent number: 8603968Abstract: Cyclic peptides having a random alternation of L-?-aminoacyl residues and aza-?3-aminoacyl residues and their uses.Type: GrantFiled: October 8, 2008Date of Patent: December 10, 2013Assignees: Centre National de la Recherche Scientifique, Universite de Rennes IInventors: Mathieu Laurencin, Céline Zatylny-Gaudin, Joël Henry, Michéle Baudy Floc'H